iShares Biotechnology ETF
963 hedge funds and large institutions have $6.38B invested in iShares Biotechnology ETF in 2021 Q4 according to their latest regulatory filings, with 187 funds opening new positions, 307 increasing their positions, 248 reducing their positions, and 66 closing their positions.
183% more first-time investments, than exits
New positions opened: 187 | Existing positions closed: 66
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
24% more repeat investments, than reductions
Existing positions increased: 307 | Existing positions reduced: 248
13% more funds holding
Funds holding: 855 → 963 (+108)
11% more call options, than puts
Call options by funds: $453M | Put options by funds: $409M
3.65% less ownership
Funds ownership: 66.96% → 63.31% (-3.7%)
10% less capital invested
Capital invested by funds: $7.1B → $6.38B (-$718M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$117M |
| 2 |
Morgan Stanley
New York
|
+$71.9M |
| 3 |
E
Ergoteles
New York
|
+$34.2M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$26.3M |
| 5 |
Jane Street
New York
|
+$24.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$203M |
| 2 |
JP Morgan Chase
New York
|
-$185M |
| 3 |
Goldman Sachs
New York
|
-$168M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$105M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$59.9M |
IBB Hedge Fund Activity: Q4 2021 in Review
963 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q4 2021, worth a combined $6.38B — down 10% from $7.1B a quarter earlier.
Buyers outnumbered sellers: 187 funds opened new IBB positions and 66 closed out — a net gain of 121 holders — while 307 added to existing stakes and 248 trimmed.
The largest buyer was Citigroup, adding an estimated $117M. The largest seller was Barclays, cutting an estimated $203M.
- 963 institutional investors held iShares Biotechnology ETF (IBB) as of Q4 2021, up from 855 in Q3 2021.
- Funds reported $6.38B of iShares Biotechnology ETF stock for Q4 2021, down 10% quarter-over-quarter.
- 187 funds opened new iShares Biotechnology ETF positions in Q4 2021 and 66 closed out, a net change of +121 holders.
- The largest iShares Biotechnology ETF buyer in Q4 2021 was Citigroup, an estimated $117M added.
- The largest iShares Biotechnology ETF seller in Q4 2021 was Barclays, an estimated $203M sold.
Based on aggregated 13F filings for Q4 2021.